Cytori Therapeutics Inc Stock Deutsche Boerse AG
Stocks
US23283K1051
Biotechnology & Medical Research
|
End-of-day quote
Deutsche Boerse AG
|
||
| - EUR | - |
|
| Market Cap | 14.42M 12.57M 11.84M 10.78M 20.22M 1.38B 20.24M 142M 54.66M 704M 54.17M 52.97M 2.27B | P/E 2026 * |
-0.4x | P/E 2027 * | -0.76x |
|---|---|---|---|---|---|
| Enterprise Value | 14.42M 12.57M 11.84M 10.78M 20.22M 1.38B 20.24M 142M 54.66M 704M 54.17M 52.97M 2.27B | EV / Sales 2026 * |
2.5x | EV / Sales 2027 * | 0.75x |
| Free-Float |
98.2% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Cytori Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Hedrick
CEO | Chief Executive Officer | 64 | 02/04/2014 |
Andrew Sims
DFI | Director of Finance/CFO | 52 | 06/02/2020 |
Daniel Ortega
CTO | Chief Tech/Sci/R&D Officer | - | 21/10/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Marc Hedrick
BRD | Director/Board Member | 64 | 01/10/2002 |
Richard Hawkins
CHM | Chairman | 77 | 25/01/2018 |
| Director/Board Member | 66 | 01/01/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.44% | +4.28% | +3.59% | +31.41% | 46.68B | |
| +0.46% | +0.06% | +43.65% | +35.76% | 44.42B | |
| +1.01% | -5.30% | +336.86% | +546.70% | 41.32B | |
| -1.01% | +4.42% | +7.10% | +89.85% | 41.58B | |
| +1.11% | +1.45% | +11.52% | +45.96% | 30.14B | |
| +0.06% | +0.20% | +24.82% | +156.17% | 17.42B | |
| +0.91% | +0.18% | - | - | 15.6B | |
| +1.05% | +7.35% | +25.85% | +43.78% | 15.54B | |
| +0.57% | +12.50% | -9.80% | - | 14.08B | |
| Average | +0.73% | +3.55% | +55.45% | +135.66% | 29.64B | |
| Weighted average by Cap. | +0.76% | +2.11% | +69.12% | +144.09% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 5.77M 5.03M 4.74M 4.32M 8.09M 553M 8.1M 56.78M 21.88M 282M 21.69M 21.2M 909M | 19.14M 16.69M 15.72M 14.31M 26.84M 1.83B 26.87M 188M 72.55M 934M 71.9M 70.31M 3.01B |
| Net income | -32.26M -28.13M -26.49M -24.12M -45.23M -3.09B -45.29M -317M -122M -1.57B -121M -118M -5.08B | -19.05M -16.61M -15.65M -14.25M -26.72M -1.83B -26.75M -187M -72.23M -930M -71.58M -69.99M -3B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
